Cocrystal Pharma Narrows Loss in Q2
Cocrystal Pharma (NASDAQ:COCP), a clinical-stage biotech focusing on antiviral drug development, released its second quarter 2025 earnings on August 14, 2025. The company’s report highlighted a smaller net loss than a year earlier, with a GAAP EPS of $0.20 compared to analyst estimates of ($0.23). This top-line GAAP EPS outperformed expectations by $0.43. The improved bottom line was primarily due to the timing of clinical study costs, particularly in research and development. However, the period also saw a sharp drop in the cash balance, with unrestricted cash decreasing from $9.9 million as of December 31, 2024, to $4.8 million as of June 30, 2025, as the company continued advancing clinical trials, underscoring near-term funding needs. Overall, the quarter reflected tightened expense management and steady progress in product development, even as the path to commercialization remains lengthy.
Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report.
Cocrystal specializes in antiviral therapies. It uses structure-based drug design—a platform that leverages computational chemistry and X-ray crystallography—to develop small molecule drugs targeting viral replication enzymes. This precise approach aims to hit highly conserved sites in viral proteins. The goal: to produce antivirals with broad effects and a high resistance barrier.
Source Fool.com
